The clinical trial report, “Multiple Sclerosis - Global Clinical Trials Review, 2025" provides an overview of Multiple Sclerosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
- Report Guidance
- The analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Multiple Sclerosis Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Multiple Sclerosis
- Jun 23, 2025: Ashvattha Therapeutics Reports the Ability To Tune Nanomedicines to Image Neuroinflammation in Multiple Sclerosis at SNMMI Annual Meeting
- Jun 22, 2025: IASO Bio Presents Promising Efficacy of Equecabtagene Autoleucel in Patients with Multiple Sclerosis in IIT study at the 11th Congress of the EAN
- Jun 13, 2025: Tiziana Life Sciences To Present at the Bio International Convention
- Jun 05, 2025: Telomir Pharmaceuticals Announces Telomir-1 Resets Body's Epigenetic Clock, Reverses DNA Methylation, Restores Gene Regulation in Werner Syndrome
- May 30, 2025: TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
- May 02, 2025: Immunic To Participate in Scientific and Industry Conferences in May
- May 02, 2025: Immunic To Participate in Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2025
- Apr 28, 2025: Sareum Holdings : Update on SDC-1801
- Apr 28, 2025: Sareum Holdings : Update on SDC-1802
- Apr 24, 2025: Dosing begins in Tiziana Life Sciences’ trial of foralumab for na-SPMS
- Apr 10, 2025: TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at American Academy of Neurology 2025 Annual Meeting
- Apr 08, 2025: TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
- Apr 08, 2025: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
- Apr 08, 2025: Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-AU8 Treatment at the American Academy of Neurology Late-Breaking Science Session
- Apr 07, 2025: TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals
- Clinical Trial Profile Snapshots
- Appendix
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About the Analyst
- Contact the Publisher
- Source
- Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region, 2025*
- Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
- Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries, 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2025*
- Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2025*
- Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
- Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
- Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2025*
- Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
- Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
- Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase, 2025*
- Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2025*
- Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
- Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
- Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region (%), 2025*
- Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
- Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2025*
- Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2025*
- Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
- Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
- Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2025*
- Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
- Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
- Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2025*
- Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2025*
- Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
- Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
- Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
- The analyst Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biogen Inc
- Novartis AG
- Sanofi
- E. Merck KG
- Teva Pharmaceutical Industries Ltd
- Bayer AG
- Roche Holding AG
- Bristol-Myers Squibb Co
- Laboratory Corp of America Holdings
- IQVIA Holdings Inc
